siste dataoppdatering: 2011/10/17, 11:39

Website lasting tid

under test: 1.01 s

kabeltilkobling (gjennomsnitt): 1.06 s

DSL forbindelse (gjennomsnitt): 1.11 s

modem (gjennomsnitt): 3.68 s

HTTP-hoder

Informasjon om DNS-servere

algeta.noMX10cluster4.eu.messagelabs.comIN3600
algeta.noMX20cluster4a.eu.messagelabs.comIN3600
algeta.noA85.221.23.130IN3600
algeta.noSOAodin.intra.itera.nohelge.itera.no27900 600 86400 3600 IN 3600
algeta.noNSodin.intra.itera.noIN3600
algeta.noNSlabbetuss.net-works.noIN3600

Mottatt fra den første DNS-server

Forespørsel til serveren "algeta.no"
Du brukte følgende DNS-server:
DNS Name: odin.intra.itera.no
DNS server adresse: 193.19.64.66#53
DNS server aliaser:

HEADER opcode: forespørsel, status: NOERROR, id: 36861
flagg: qr aa rd ra forespørsel: 1, Svar: 6, AUTHORITY: 0, ekstra: 4

forespørsel DEL:
algeta.no. IN ANY

Svar DEL:
algeta.no. 3600 IN A 85.221.23.130
algeta.no. 3600 IN NS labbetuss.net-works.no.
algeta.no. 3600 IN NS odin.intra.itera.no.
algeta.no. 3600 IN SOA odin.intra.itera.no. helge.itera.no. 27 900 600 86400 3600
algeta.no. 600 IN MX 20 cluster4a.eu.messagelabs.com.
algeta.no. 3600 IN MX 10 cluster4.eu.messagelabs.com.

DEL Notes:
labbetuss.net-works.no. 1440 IN A 77.40.170.151
odin.intra.itera.no. 1200 IN A 193.19.64.66
cluster4a.eu.messagelabs.com. 666 IN A 216.82.251.230
cluster4a.eu.messagelabs.com. 666 IN A 85.158.139.103

Mottatt 283 bytes fra adresse 193.19.64.66#53 i tiden på 104 ms

mottatt fra andre DNS-server

Forespørsel til serveren "algeta.no"
Du brukte følgende DNS-server:
DNS Name: labbetuss.net-works.no
DNS server adresse: 77.40.170.151#53
DNS server aliaser:

HEADER opcode: forespørsel, status: NOERROR, id: 41193
flagg: qr aa rd forespørsel: 1, Svar: 6, AUTHORITY: 0, ekstra: 1

forespørsel DEL:
algeta.no. IN ANY

Svar DEL:
algeta.no. 3600 IN SOA odin.intra.itera.no. helge.itera.no. 27 900 600 86400 3600
algeta.no. 3600 IN NS labbetuss.net-works.no.
algeta.no. 3600 IN NS odin.intra.itera.no.
algeta.no. 3600 IN A 85.221.23.130
algeta.no. 3600 IN MX 20 cluster4a.eu.messagelabs.com.
algeta.no. 3600 IN MX 10 cluster4.eu.messagelabs.com.

DEL Notes:
labbetuss.net-works.no. 1440 IN A 77.40.170.151

Mottatt 235 bytes fra adresse 77.40.170.151#53 i tiden på 103 ms

underdomener (de første 50)

Skrivefeil (feilstaver)

zlgeta.no
slgeta.no
wlgeta.no
qlgeta.no
akgeta.no
apgeta.no
aogeta.no
alfeta.no
alveta.no
albeta.no
alheta.no
alyeta.no
alteta.no
algwta.no
algsta.no
algdta.no
algrta.no
alg4ta.no
alg3ta.no
algera.no
algefa.no
algega.no
algeya.no
alge6a.no
alge5a.no
algetz.no
algets.no
algetw.no
algetq.no
lgeta.no
ageta.no
aleta.no
algta.no
algea.no
alget.no
lageta.no
agleta.no
alegta.no
algtea.no
algeat.no
aalgeta.no
allgeta.no
alggeta.no
algeeta.no
algetta.no
algetaa.no

Sted

IP: 85.221.23.130

kontinent: EU, land: Norway (NOR), by:

Website verdi

rang i trafikken statistikken:

Det er ikke nok data til å beregne nettstedet verdi.

Grunnleggende informasjon

nettsted bygger ved hjelp av CSS

code vekt: 18.72 KB

tekst per all kode ratio: 19 %

tittel: Algeta.com

beskrivelse:

søkeord:

koding: ISO-8859-1

språk: no

Website kodeanalyse

et ord setninger gjentas minst tre ganger

setningAntall
20117
to6
Algeta5
and5
September5
is4
Alpharadin4
with4
at3
III3
for3
of3
Corporate3

to ord setninger gjentas minst tre ganger

setningAntall
September 20115
2011 Algeta3

tre ord setninger gjentas minst tre ganger

setningAntall
September 2011 Algeta3

B tags

U tags

I tags

bilder

file namealternative teksten

overskrifter

H1

Algeta is a focused oncology company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.

H2

H3

H4

H5

H6

interne lenker

adresseanker tekst
Home
About us
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Products
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Clinical trials
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
R & D
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
News & Media
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Investors
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Partners
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Contact
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
About us
About Algeta
Corporate Strategy
Management
Board of Directors
Code of Ethics
Products
Pipeline
Alpharadin
TTC
Clinical trials
ALSYMPCA
BC1-09 Breast
BC1-10 Combo
R & D
Technology Overview
Alpha-Pharmaceuticals
News & Media
Press releases
Events
Publications PDF
Pictures & logo
Media contact
Subscription
Investors
Share Price Information
Reports & Presentations
Webcast
Main Shareholders
Oslo Stock Exchange
OSE Announcements
Analyst Coverage
Financial Calendar
AGM 2011
Corporate Governance
Board of Directors
Management
Subscription
IR contacts
Partners
Overview
Contact
Contact details
Directions
Careers
About us
Products
Clinical trials
R & D
News & Media
Investors
Partners
Contact
Learn more >
Investors
Products
How to find us
Disclaimer
Privacy statement

eksterne linker

adresseanker tekst
Algeta to Host Investor Meeting, Webcast and Conference Call to Discuss Positive Phase III Trial Results for Alpharadin
Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases
Algeta to Present at Forthcoming Life Sciences Investor Conferences
Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress
Algeta appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs
Webcast
Annual Report 2010
Webcast